JP2023502276A5 - - Google Patents

Info

Publication number
JP2023502276A5
JP2023502276A5 JP2022529715A JP2022529715A JP2023502276A5 JP 2023502276 A5 JP2023502276 A5 JP 2023502276A5 JP 2022529715 A JP2022529715 A JP 2022529715A JP 2022529715 A JP2022529715 A JP 2022529715A JP 2023502276 A5 JP2023502276 A5 JP 2023502276A5
Authority
JP
Japan
Prior art keywords
vaccine
formula
agent according
administered
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061594 external-priority patent/WO2021102320A1/en
Publication of JP2023502276A publication Critical patent/JP2023502276A/ja
Publication of JP2023502276A5 publication Critical patent/JP2023502276A5/ja
Priority to JP2025178576A priority Critical patent/JP2026016535A/ja
Pending legal-status Critical Current

Links

JP2022529715A 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法 Pending JP2023502276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025178576A JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025178576A Division JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Publications (2)

Publication Number Publication Date
JP2023502276A JP2023502276A (ja) 2023-01-23
JP2023502276A5 true JP2023502276A5 (enExample) 2023-11-29

Family

ID=75980043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529715A Pending JP2023502276A (ja) 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Country Status (11)

Country Link
US (1) US20230053458A1 (enExample)
EP (1) EP4061411A4 (enExample)
JP (2) JP2023502276A (enExample)
KR (1) KR20220107001A (enExample)
CN (1) CN114845731A (enExample)
AU (1) AU2020386971A1 (enExample)
BR (1) BR112022009924A2 (enExample)
CA (1) CA3162238A1 (enExample)
IL (1) IL293091A (enExample)
WO (1) WO2021102320A1 (enExample)
ZA (1) ZA202205546B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
MX2014013637A (es) * 2012-05-07 2015-02-05 Sanofi Sa Metodos para prevencion de la formacion de biopelicula.
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Similar Documents

Publication Publication Date Title
ES2275499T3 (es) Vacuna contra streptococcus pneumoniae.
CN1154509C (zh) 含有混合载体的多价疫苗组合物
US8604184B2 (en) Chemically programmable immunity
ES2321892T3 (es) Composiciones de beta-glucanos e inmunoglobulinas especificas.
JP2023502276A5 (enExample)
US7422746B2 (en) Chemically programmable immunity
TW200914042A (en) Vaccine
WO2020259076A1 (zh) 一种糖缀合物及其用途
JP2021001182A5 (enExample)
Xu et al. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein
CN101472605A (zh) 用于舌下给药疫苗的药物组合物，制备该药物组合物的方法以及其应用
JP2009514840A5 (enExample)
Pajon et al. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice
Merli et al. Management of vaccinations in patients with non‐Hodgkin lymphoma
ES2366735B1 (es) Vacuna frente a acinetobacter baumannii.
JP2021066727A5 (enExample)
WO2023025002A1 (zh) 一种肺炎球菌结合疫苗组合物
CN101130071A (zh) 疫苗
Akter et al. Glycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers
WO2023025003A1 (zh) 一种肺炎球菌结合疫苗制备方法
WO2013027063A1 (en) Chemically programmable immunity
Simoneaux IDWeek 2014, Philadelphia, Pennsylvania, USA, October 7-12, 2014
US20150079129A1 (en) Vaccine
MXPA01009455A (en) Vaccine
TW201008578A (en) Vaccine composition